drugset / Trial / NCT05952986
A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, placebo-controlled, and double-blind study to evaluate the safety and bridging PK profile of FB825 for single SC administration in healthy adults.
Timeline
- Start
- 2023-05-03
- Primary completion
- 2024-03-26
- Completion
- 2024-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FB825 | Unknown | 300 mg | Subcutaneous |
| Subject | FB825 | Unknown | 450 mg | Subcutaneous |